Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of April 2013. The report discloses a corporate governance event regarding a substantial shareholder rather than operational or financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice of shareholding changes and contains no financial statements.
Material Changes
- Cessation of Substantial Holder Status: Baywick Pty Ltd ceased to be a substantial holder of Prana Biotechnology Limited on April 8, 2013.
- Reason for Change: The reduction in interest was due to the dilution of Baywick's holding resulting from the issuance of new shares by the company. No shares were sold by Baywick Pty Ltd.
- Volume of Change: The dilution affected 17,811,000 ordinary shares (ORD).
- Consideration: Nil consideration was given for this change in interest.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risks, contingencies, or unusual items. The document is strictly a statutory notice under Section 671B of the Corporations Act 2001.
Investor Verification Checklist
- Verify the total number of issued shares post-April 8, 2013, to calculate Baywick Pty Ltd's new percentage ownership.
- Confirm the purpose of the new share issuance that caused the dilution (e.g., capital raise, employee options).
- Review the previous substantial holding notice dated October 9, 2012, to compare the prior ownership percentage.
- Check for any subsequent filings regarding Baywick Pty Ltd's current status as a shareholder.